Lai Meng Looi

Prof. Dr. Lai Meng Looi

orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
JWJan J. Weening
Jan J. Weening
VDVivette D. D’agati
Vivette D. D’agati
MSMelvin M. Schwartz
Melvin M. Schwartz
SSSurya V. Seshan
Surya V. Seshan
CACharles E. Alpers
Charles E. Alpers
MNMichio Nagata
Michio Nagata
The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving <50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving ≥50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions]. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.

1 February 2004 in Kidney International
Verified
Journal Article
Closed access
JWJan J. Weening
Jan J. Weening
ONON Behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification Oflupus Nephritis
ON Behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification Oflupus Nephritis
VDVivette D. D'AGati
Vivette D. D'AGati
MSMelvin M. Schwartz
Melvin M. Schwartz
SSSurya V. Seshan
Surya V. Seshan
MNMichio Nagata
Michio Nagata

1 May 2018 in The Lancet
Verified
Journal Article
Closed access
MWMichael L Wilson
Michael L Wilson
KFKenneth A Fleming
Kenneth A Fleming
MKModupe A Kuti
Modupe A Kuti
Lai Meng LooiLai Meng Looi
Lai Meng Looi
NLNestor Lago
Nestor Lago
KRKun Ru
Kun Ru

1 May 2018 in The Lancet
Verified
Journal Article
Closed access
SSShahin Sayed
Shahin Sayed
WCWilliam Cherniak
William Cherniak
MLMark Lawler
Mark Lawler
STSoo-Yong Tan
Soo-Yong Tan
WSWafaa El Sadr
Wafaa El Sadr
KFKenneth A Fleming
Kenneth A Fleming

25 September 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
K(Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
Suhwan ChangSuhwan Chang
Suhwan Chang
RWRui-Hong Wang
Rui-Hong Wang
KAKeiko Akagi
Keiko Akagi
KKKyung-Ae Kim
Kyung-Ae Kim
SSShyam K Sharan
Shyam K Sharan

1 March 2018 in The Lancet
Verified
Journal Article
Closed access
DJDean T Jamison
Dean T Jamison
AAAla Alwan
Ala Alwan
CMCharles N Mock
Charles N Mock
RNRachel Nugent
Rachel Nugent
DWDavid Watkins
David Watkins
KZKun Zhao
Kun Zhao